BioNTech (NASDAQ:BNTX) Posts Quarterly Earnings Results, Beats Expectations By $0.70 EPS

BioNTech (NASDAQ:BNTX) announced its earnings results on Monday. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70, RTT News reports. The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.90 earnings per share. BioNTech updated its FY 2025 guidance to EPS.

BioNTech Stock Performance

BNTX opened at $105.35 on Tuesday. The company has a market capitalization of $25.26 billion, a PE ratio of -50.17 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business has a fifty day simple moving average of $116.76 and a 200 day simple moving average of $113.06. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on BNTX shares. Berenberg Bank started coverage on BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target on the stock. Canaccord Genuity Group raised their price target on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. Wells Fargo & Company initiated coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price on the stock. Truist Financial initiated coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 target price on the stock. Finally, BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.